AIHTA - Publications - Search - Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC)

Wolf, S. (2021): Pembrolizumab (Keytruda) in combination with Lenvatinib (Kisplyx) for the firstline treatment of advanced renal cell carcinoma (RCC). Oncology Fact Sheet Nr. 67.

[thumbnail of Oncology Fact Sheet Nr.67.pdf]
Preview
PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
124kB

Item Type:Oncology Fact Sheet
Subjects:QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WB Practice of medicine > WB 300-962 Therapeutics
WJ Urogenital system > WJ 300-378 Kidney
Language:English
Series Name:Oncology Fact Sheet Nr. 67
Deposited on:12 Nov 2021 15:48
Last Modified:12 Nov 2021 15:48

Repository Staff Only: item control page